Q2 EPS Estimates for Beta Bionics Raised by Leerink Partnrs

Beta Bionics, Inc. (NASDAQ:BBNX) – Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for Beta Bionics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.46) for the quarter, up from their previous forecast of ($0.50). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.65) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.35) EPS and FY2029 earnings at ($0.88) EPS.

A number of other analysts have also commented on BBNX. Piper Sandler started coverage on Beta Bionics in a report on Monday, February 24th. They issued an “overweight” rating and a $26.00 target price for the company. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a report on Thursday, February 20th. Robert W. Baird started coverage on Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target for the company. Bank of America assumed coverage on Beta Bionics in a research note on Monday, February 24th. They issued a “buy” rating for the company. Finally, Lake Street Capital initiated coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $30.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Stock Down 7.5 %

Shares of BBNX opened at $13.79 on Friday. Beta Bionics has a twelve month low of $8.89 and a twelve month high of $24.50. The firm’s 50 day moving average price is $12.64.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Institutional Trading of Beta Bionics

Several hedge funds have recently modified their holdings of BBNX. Charles Schwab Investment Management Inc. purchased a new stake in Beta Bionics during the first quarter valued at $1,244,000. Jennison Associates LLC purchased a new stake in shares of Beta Bionics during the 1st quarter valued at about $828,000. TD Asset Management Inc bought a new position in shares of Beta Bionics in the 1st quarter valued at about $488,000. Evanson Asset Management LLC purchased a new position in Beta Bionics in the first quarter worth about $475,000. Finally, Values First Advisors Inc. purchased a new stake in Beta Bionics during the first quarter valued at approximately $457,000.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.